| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/10/1999 | WO1999044603A1 Composition and method for treating macular disorders |
| 09/10/1999 | WO1999044599A1 Therapeutic treatment for renal dysfunction |
| 09/10/1999 | WO1999044595A2 Pharmaceutical compositions for ulcer |
| 09/10/1999 | WO1999044592A1 Anti-asthma therapy |
| 09/10/1999 | WO1999044508A1 Integrated poration, harvesting and analysis device, and method therefor |
| 09/10/1999 | WO1999044507A1 Integrated tissue poration, fluid harvesting and analysis device, and method therefor |
| 09/10/1999 | WO1999020756A3 Human toll homologues |
| 09/10/1999 | WO1998053839A3 Anti-cancer products for treating cystic fibrosis |
| 09/10/1999 | WO1998005356A8 NOVEL FtsL |
| 09/10/1999 | CA2637760A1 Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
| 09/10/1999 | CA2323749A1 Composition and method for treating macular disorders |
| 09/10/1999 | CA2323176A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases |
| 09/10/1999 | CA2323173A1 Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma |
| 09/10/1999 | CA2323172A1 Therapeutic treatment for renal dysfunction |
| 09/10/1999 | CA2323160A1 Photothermal structure for biomedical applications, and method therefor |
| 09/10/1999 | CA2323158A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection |
| 09/10/1999 | CA2322664A1 Enhanced prodrug activation |
| 09/10/1999 | CA2322592A1 Use of a peptide or antibody in the manufacture of a medicament for treating an erbb protein medicated tumor in combination with irradiation |
| 09/10/1999 | CA2322425A1 Novel fdrg protein and nucleic acid molecules and uses therefor |
| 09/10/1999 | CA2322201A1 Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism |
| 09/10/1999 | CA2321737A1 Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid |
| 09/10/1999 | CA2321685A1 Combination of a selective nmda nr2b antagonist and an opioid analgesic |
| 09/10/1999 | CA2321171A1 Conjugates useful in the treatment of prostate cancer |
| 09/10/1999 | CA2249661A1 Novel compounds |
| 09/08/1999 | EP0940391A2 Quinoline derivatives as tachykinin NK3 receptor antagonists |
| 09/08/1999 | EP0940143A2 Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma |
| 09/08/1999 | EP0940142A2 Use of PKC inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases |
| 09/08/1999 | EP0940141A2 Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection |
| 09/08/1999 | EP0939832A1 Mitochondrial dna mutations that segregate with late onset diabetes mellitus |
| 09/08/1999 | EP0939821A2 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 09/08/1999 | EP0939815A1 IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO INTEGRIN AND IS INVOLVED IN INTEGRIN-MEDIATED SIGNAL TRANSDUCTION |
| 09/08/1999 | EP0939812A2 Novel human macrophage antigen |
| 09/08/1999 | EP0939809A2 Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses |
| 09/08/1999 | EP0939804A1 NEUTROKINE alpha |
| 09/08/1999 | EP0939802A1 spsA POLYNUCLEOTIDES AND POLYPEPTIDES |
| 09/08/1999 | EP0939654A1 Association of no syntase inhibitors with trappers of oxygen reactive forms |
| 09/08/1999 | EP0939651A1 Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes |
| 09/08/1999 | EP0939643A1 Immunomodulating compounds comprising d-isomers of amino acids |
| 09/08/1999 | EP0939641A1 Topical products as prophylactic or curative agents for bacterial skin infections |
| 09/08/1999 | EP0939635A1 Improved intraocular irrigating solution containing a polyamine antagonist |
| 09/08/1999 | EP0939633A1 Treatment of sepsis-induced acute renal failure and renal vasoconstriction and catecholamine-induced renal and mesenteric vasoconstriction |
| 09/08/1999 | EP0749415B1 Benzamide analogs, useful as parp (adp-ribosyltransferase, adprt) dna repair enzyme inhibitors |
| 09/08/1999 | CN1228028A Use of histamine for therapeutic purposes |
| 09/08/1999 | CN1228026A Combinations comprising VX 478, zidovudine, FTC and/or 3TC for use in treatment of HIV |
| 09/07/1999 | US5948824 Use of a chemical agent for reducing the changes in waistline and the effect of constipation due to the taking of other agents |
| 09/07/1999 | US5948780 Administering a metalloproteinase inhibitor |
| 09/07/1999 | US5948773 Formulation comprising antibacterial substance and antiulcer substance |
| 09/07/1999 | US5948772 Useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass. |
| 09/07/1999 | US5948752 Suppressory agents against hypercoagulation |
| 09/07/1999 | US5948669 As probes and primers; for diagnosis and treatment of osteoporosis, oral diseases, paget's disease; antiarthritic agents, anticarcinogenic/antitumor/antimetastasis agents |
| 09/07/1999 | US5948657 Phenylalanyl-tRNA synthetase from Staphylococcus aureus |
| 09/07/1999 | US5948642 Polynucleotide from staphylococcus aureus which codes for resolvase polypeptide; for diagnosis of infections; as bactericides; for screening for novel antibiotics; treatment of toxic shock syndrome |
| 09/07/1999 | US5948638 TNF receptor death domain ligand proteins |
| 09/07/1999 | US5948626 Method of detecting human phospholipase inhibitor |
| 09/07/1999 | US5948443 Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
| 09/07/1999 | US5948401 Cationic therapeutic systems |
| 09/07/1999 | CA2147881C Dithiocarbamates for the treatment of atherosclerosis and other cardiovascular and inflammatory diseases |
| 09/07/1999 | CA1340722C Pharmaceutical composition for the treatment of high blood pressure |
| 09/02/1999 | WO1999043851A1 Hla linked pre-eclampsia and miscarriage susceptibility gene |
| 09/02/1999 | WO1999043832A2 Human proteinase molecules |
| 09/02/1999 | WO1999043831A1 Cprot03, a human cysteine protease |
| 09/02/1999 | WO1999043814A1 Therapeutic blockade of icer synthesis to prevent icer-mediated inhibition of immune cell activity |
| 09/02/1999 | WO1999043809A2 Protease-activated receptor 4 and uses thereof |
| 09/02/1999 | WO1999043807A2 Human channel-related molecules |
| 09/02/1999 | WO1999043692A1 pyrH GENE AND PROTEIN OF STREPTOCOCCUS PNEUMONIAE |
| 09/02/1999 | WO1999043354A2 Method for treating painful conditions of the anal region and compositions therefor |
| 09/02/1999 | WO1999043343A1 Novel peptide copolymer compositions |
| 09/02/1999 | WO1999043339A1 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof |
| 09/02/1999 | WO1999043332A1 Antitumor combination comprising epirubicin and gemcitabine for the treatment of non-small-cell lung cancer |
| 09/02/1999 | WO1999043329A1 Biochemical compositions used in human treatment |
| 09/02/1999 | WO1999043327A1 Antimicrobial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith |
| 09/02/1999 | WO1999043323A1 Compounds and methods for chemosensitizing multidrug resistant cells |
| 09/02/1999 | WO1999043319A1 Agents with serotonin-related activity for the treatment for sleep apnea |
| 09/02/1999 | WO1999043317A1 Necrosis-affine compounds and the utilization thereof in order to produce preparations for pharmacotherapy |
| 09/02/1999 | WO1999043314A1 Farnesyl-protein transferase inhibitors |
| 09/02/1999 | WO1999043310A2 20-hete antagonists and agonists |
| 09/02/1999 | WO1999043210A1 Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist |
| 09/02/1999 | WO1999021540A3 Method of reducing craving in mammals |
| 09/02/1999 | WO1998040052A9 Cationic lipid compositions targeting angiogenic endothelial cells |
| 09/02/1999 | WO1998034632A9 Compounds and compositions for delivering active agents |
| 09/02/1999 | WO1998030693A9 Tumor necrosis factor receptor 5 |
| 09/02/1999 | WO1998027113A8 Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5 |
| 09/02/1999 | CA2366915A1 Biochemical compositions used in human treatment |
| 09/02/1999 | CA2321993A1 Therapeutic blockade of icer synthesis to prevent icer-mediated inhibition of immune cell activity |
| 09/02/1999 | CA2321869A1 Human proteinase molecules |
| 09/02/1999 | CA2321719A1 Farnesyl-protein transferase inhibitors |
| 09/02/1999 | CA2321667A1 Human channel-related molecules |
| 09/02/1999 | CA2321223A1 Hla linked pre-eclampsia and miscarriage susceptibility gene |
| 09/02/1999 | CA2321142A1 Protease-activated receptor 4 and uses thereof |
| 09/02/1999 | CA2320289A1 Novel peptide copolymer compositions |
| 09/02/1999 | CA2319123A1 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof |
| 09/02/1999 | CA2318778A1 Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist |
| 09/01/1999 | EP0939124A2 MGBP1 sequences |
| 09/01/1999 | EP0939123A2 Estrogen receptor-related polypetide SBPERR4 |
| 09/01/1999 | EP0938676A1 Combinatorial process for preparing thiazolidinone libraries |
| 09/01/1999 | EP0938554A1 Human protein kinase c inhibitor homolog |
| 09/01/1999 | EP0938483A2 Muscarinic antagonists |
| 09/01/1999 | EP0938336A1 A method for enhancing long-term memory in a subject and uses thereof |
| 09/01/1999 | EP0938333A1 Method of enhancing the delivery of growth factors |
| 09/01/1999 | EP0938330A1 Use of lh-rh antagonists as diagnostic agent |